DEALS: GSK, Targacept ink $1.5B pain deal

DEALS

WHO

WITH

WHAT

SCOOP

GSK

Targacept

$1.5B deal

GSK and Targacept have inked a discovery, development and commercialization deal for therapeutics that target specified neuronal nicotinic receptors.

Meda

MedPointe

$800M buyout

Meda said that MedPointe's products, which focus on the areas of allergy, respiratory and pain, are a perfect fit for Meda's portfolio.

Genstar Capital

PRA International

$744 buyout

Genstar Capital has struck a deal to buy PRA International for $744 million, a premium of about 13 percent on PRA's stock price. PRA gets 50 days to solicit a better offer.

Merck

NovaCardia

$350M buyout

NovaCardia has a drug--KW-3902--in late-stage studies for congestive heart failure.

Pfizer Global R&D

Hydra Biosciences

$195M deal

Hydra stands to gain up to $195 million in up front and milestone payments the first product developed from the Transient Receptor Potential channel family.

SurModics

Brookwood Pharmaceuticals

$62M sale

The Southern Research Institute has sold Brookwood Pharmaceuticals to SurModics for $40M up front and up to $22M in milestones. Both SurModics and Brookwood specialize in drug delivery technologies.

Cell Therapeutics

Systems Medicine

$35M buyout

Systems Medicine is developing a genetically engineered drug called Brostallicin, which Cell Therapeutics believes is a "perfect fit" for its pipeline.

Antares Pharma

Jazz Pharmaceuticals

$16.5M development and licensing deal

The deal is for the development of therapeutics for an unnamed CNS disorder based on Antares' Advanced Transdermal Delivery system.